These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 18163880)

  • 1. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
    Turner BC; Eves T; Refaeli Y
    DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.
    Koss B; Ryan J; Budhraja A; Szarama K; Yang X; Bathina M; Cardone MH; Nikolovska-Coleska Z; Letai A; Opferman JT
    Oncotarget; 2016 Mar; 7(10):11500-11. PubMed ID: 26862853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.
    Willis SN; Fletcher JI; Kaufmann T; van Delft MF; Chen L; Czabotar PE; Ierino H; Lee EF; Fairlie WD; Bouillet P; Strasser A; Kluck RM; Adams JM; Huang DC
    Science; 2007 Feb; 315(5813):856-9. PubMed ID: 17289999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.
    Erlacher M; Labi V; Manzl C; Böck G; Tzankov A; Häcker G; Michalak E; Strasser A; Villunger A
    J Exp Med; 2006 Dec; 203(13):2939-51. PubMed ID: 17178918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
    Billard C
    Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
    Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
    J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
    Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
    Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
    Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
    Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW
    Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
    Chen L; Willis SN; Wei A; Smith BJ; Fletcher JI; Hinds MG; Colman PM; Day CL; Adams JM; Huang DC
    Mol Cell; 2005 Feb; 17(3):393-403. PubMed ID: 15694340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.
    Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G
    Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
    Raghav PK; Verma YK; Gangenahalli GU
    Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 homology domain 3-only proteins Puma and Bim mediate the vulnerability of CA1 hippocampal neurons to proteasome inhibition in vivo.
    Tsuchiya T; Bonner HP; Engel T; Woods I; Matsushima S; Ward MW; Taki W; Henshall DC; Concannon CG; Prehn JH
    Eur J Neurosci; 2011 Feb; 33(3):401-8. PubMed ID: 21198986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New dimension in therapeutic targeting of BCL-2 family proteins.
    Besbes S; Mirshahi M; Pocard M; Billard C
    Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity.
    Ponassi R; Biasotti B; Tomati V; Bruno S; Poggi A; Malacarne D; Cimoli G; Salis A; Pozzi S; Miglino M; Damonte G; Cozzini P; Spyrakis F; Campanini B; Bagnasco L; Castagnino N; Tortolina L; Mumot A; Frassoni F; Daga A; Cilli M; Piccardi F; Monfardini I; Perugini M; Zoppoli G; D'Arrigo C; Pesenti R; Parodi S
    Cell Cycle; 2008 Oct; 7(20):3211-24. PubMed ID: 18843207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.